Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. AGC Inc.
  6. News
  7. Summary
    5201   JP3112000009

AGC INC.

(5201)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AGC : Biologics Enters Agreement to Acquire Facility in Longmont, Colorado, U.S.(PDF 409KB)

07/01/2021 | 11:12pm EDT

News Release

AGC Biologics Enters Agreement to Acquire Facility in Longmont, Colorado, U.S.

―Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities and Offerings―

Tokyo, July 2, 2021 - AGC (AGC Inc.; Headquarters: Tokyo; President: Yoshinori Hirai), a world-leading manufacturer of glass, chemicals, and high-tech materials, has announced that its biopharmaceutical CDMO*1 subsidiary, AGC Biologics (Headquarters: United States), has signed an agreement with Novartis Gene Therapies (Headquarters: United States) to purchase a cell and gene therapy manufacturing facility located in Longmont, Colorado, U.S. The closing of the transaction is pending completion of final due diligence.

The addition of this facility follows last year's acquisition of the Italian company MolMed (now AGC Biologics S.p.A., referred to as "Milan Site"),which is currently undergoing expansion previously announced. With the needs of customers rapidly increasing in the fast-growingfield of gene and cell therapy, AGC Biologics is securing further manufacturing capacity, this time in the United States, the world-leadingmarket in this field. Once the transaction closes, the facility will be integrated into AGC Biologics' network, and services will be extended incorporating the Milan Site's robust experience providing commercial GMP*2-compliantcell and gene therapy CDMO services, utilizing the facility's large floor space at over 60,000 square meters. Further, the Heidelberg Site has an established plasmid DNA production service, enabling AGC Biologics to offer end-to-endcell and gene services. This facility will become part of that offering.

The facility to be purchased

Under its AGC plus 2.0 management policy, AGC Group has positioned its Life Science business including its biopharmaceutical CDMO services, as one of its strategic businesses. The Group has been expanding its business through multiple acquisitions and capital investments for its CDMO services using mammalian cells and microorganisms, as well as in synthetic pharmaceutical and agrochemical services. Furthermore in 2020, the Group expanded the scope of its CDMO business into the rapidly growing field of cell and gene therapy. The sales target for the Group's Life Science business is 180 billion yen or more for 2025.

The AGC Group will work to provide its customers in each region with globally unified, high-quality services, contributing to the well-being of patients and the wider society as a whole.

MEDIA INQUIRIES

Kazumi Tamaki, General Manager, Corporate Communications & Investor Relations Division AGC Inc.

(Contact: Tomoko Nakao; Tel: +81-3-3218-5603;E-mail:info-pr@agc.com

*Handling of personal information is governed by our privacy policy.

News Release

Notes:

*1 CDMO: Contract Development & Manufacturing Organization. A company which is contracted on behalf of another company to provide product manufacturing services as well as the development of manufacturing processes.

*2 GMP: Good Manufacturing Practice. A standard for the manufacture and quality management of pharmaceutical products.

REFERENCE

AGC Group's CDMO Business Sites

MEDIA INQUIRIES

Kazumi Tamaki, General Manager, Corporate Communications & Investor Relations Division AGC Inc.

(Contact: Tomoko Nakao; Tel: +81-3-3218-5603;E-mail:info-pr@agc.com

*Handling of personal information is governed by our privacy policy.

Disclaimer

AGC - Asahi Glass Co. Ltd. published this content on 02 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 July 2021 03:01:26 UTC.


ę Publicnow 2021
All news about AGC INC.
09/13AGC : Biologics to Build New Messenger RNA Capacity at its Heidelberg Facility
PU
09/08AGC : Photovoltaic Glass Adopted by Singapore Institute of Technology
PU
09/07AGC : Sponsors the Expo 2020 Dubai JAPAN PAVILION
PU
08/03AGC : and JAMSTEC Succeed in Developing World's First Highly Accurate Numerical Method to ..
PU
08/03AGC : (Progress of Disclosure Matters) Notice regarding Closing of Transfer of Architectur..
PU
08/02AGC : Financial Results for the Six Months ended June 30, 2021
PU
08/02AGC : Consolidated Financial Results for the Six Months ended June 30, 2021(PDF 189KB)
PU
08/02AGC : Consolidated Financial Results for the Six Months ended June 30, 2021 (IFRS basis)
PU
08/02AGC : Notice regarding Revision to Full Year Consolidated Financial Forecasts, Dividend Fo..
PU
08/02AGC Inc. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2021
CI
More news
Financials
Sales 2021 1 653 B 14 921 M 14 921 M
Net income 2021 118 B 1 066 M 1 066 M
Net Debt 2021 526 B 4 751 M 4 751 M
P/E ratio 2021 11,1x
Yield 2021 3,34%
Capitalization 1 338 B 12 089 M 12 082 M
EV / Sales 2021 1,13x
EV / Sales 2022 1,06x
Nbr of Employees 56 179
Free-Float 88,0%
Chart AGC INC.
Duration : Period :
AGC Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGC INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 5 900,00 JPY
Average target price 6 087,00 JPY
Spread / Average Target 3,17%
EPS Revisions
Managers and Directors
Takuya Shimamura President, CEO & Representative Director
Shinji Miyaji CFO, Representative Director & Executive VP
Yoshinori Hirai Director, CTO & Senior Managing Executive Officer
Yasuchika Hasegawa Independent Outside Director
Hiroyuki Yanagi Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
AGC INC.63.89%11 860
SAINT-GOBAIN62.13%38 217
ASSA ABLOY AB30.32%33 946
MASCO CORPORATION2.88%14 007
XINYI GLASS HOLDINGS LIMITED8.08%13 066
FORTUNE BRANDS HOME & SECURITY, INC.8.81%12 860